Trans-pulmonary Biomarkers in Pulmonary Hypertension

Examination of Trans-pulmonary Biomarkers in Pulmonary Hypertension: a Potential Step Towards Personalized Therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01961232

Enrollment

100

Registered

2013-10-11

Start date

2013-08-01

Completion date

2027-06-01

Last updated

2026-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Hypertension

Keywords

Pulmonary Hypertension, biomarker, cardiac, circulation, heart disease, lung disease

Brief summary

The investigators are testing whether the addition of Pulmonary Hypertension-related biomarkers, measured across the pulmonary circulation, to the standard hemodynamic evaluation for Pulmonary Hypertension will lead to more informed choices of Pulmonary Hypertension therapy and improved patient outcomes.

Detailed description

Eligible participants with known or suspected Pulmonary Hypertension undergoing a clinically indicated right heart catheterization may be enrolled. Clinical data and blood samples will be analyzed.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥ 18 years old * Undergoing RHC for PH evaluation

Exclusion criteria

* Anemia defined as Hgb \< 10 g/dL and HCT \< 30 * Pregnancy at the time of RHC (as assessed by urine or serum pregnancy test on the day of the procedure) * Left ventricular ejection fraction ≤ 40% * Atrial fibrillation at the time of RHC (as defined by telemetry monitoring or EKG on the day of the procedure) * IPF, CTEPH, COPD/OSA as the dominant etiology of PH * Patient is currently taking PH medication or long-acting nitrates at the time of their RHC.

Design outcomes

Primary

Measure	Time frame
Differences in Pulmonary Hypertension biomarkers in patients evaluated for Pulmonary Hypertension	At baseline

Secondary

Measure	Time frame
Vasodilator-induced changes in Pulmonary Vascular Resistance (PVR)	At baseline
Vasodilator-induced changes in Pulmonary Hypertension biomarkers	At baseline

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORKen Monahan, MD

Vanderbilt University Medical Center

Outcome results